Taro to Release Third Quarter Results on January 24, 2023

1/19/23 5:02:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TARO alert in real time by email

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after the close of market on Tuesday, January 24, 2023.

The release will be accessible on Taro's website at www.taro.com.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005893/en/

Get the next $TARO alert in real time by email

Date	Price Target	Rating	Analyst
1/18/2024	$43.00	Buy → Neutral	H.C. Wainwright
1/31/2022	$75.00 → $73.00	Buy	HC Wainwright & Co.
1/18/2022	$82.00 → $75.00	Buy	HC Wainwright & Co.
7/28/2021	$80.00 → $82.00	Buy	HC Wainwright & Co.

Taro to Release Third Quarter Results on January 24, 2023

Chat with this insight

Recent Analyst Ratings for
$TARO

$TARO
Press Releases

Fastest customizable press release news feed in the world

Sun Pharma Completes Taro Merger

Taro Shareholders Approve Merger with Sun Pharma

Taro Provides Results for Year Ended March 31, 2024

$TARO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd.

SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)

SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)

$TARO
SEC Filings

SEC Form 15F-12B filed by Taro Pharmaceutical Industries Ltd.

SEC Form 25-NSE filed by Taro Pharmaceutical Industries Ltd.

Amendment: SEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd.

$TARO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Taro Pharm downgraded by H.C. Wainwright with a new price target

HC Wainwright & Co. reiterated coverage on Taro Pharmaceutical Indus with a new price target

HC Wainwright & Co. reiterated coverage on Taro Pharmaceutical Indus with a new price target

$TARO
Leadership Updates

Live Leadership Updates

Taro Appoints New Chief Financial Officer

Taro Announces Resignation of Chief Financial Officer

$TARO
Market Insights

Live Market Insights

Sun Pharmaceutical And Taro Pharmaceutical Industries' Merger Agreement Was Approved By The Affirmative Vote Of Taro Shareholders

Taro Pharmaceutical Indus Q4 Adj EPS $0.43 Beats $0.31 Estimate, Sales $164.941M Beat $156.062M Estimate

Krensavage Asset Management Remains Opposed to Sun Pharma's Predatory Bid for Taro Pharma

$TARO
Financials

Live finance-specific insights

Taro to Release Third Quarter Results on January 25, 2024

Taro to Release Second Quarter Results on October 26, 2023

Taro to Release First Quarter Results on July 26, 2023

Taro to Release Third Quarter Results on January 24, 2023

Chat with this insight

Recent Analyst Ratings for $TARO

$TARO Press Releases

Fastest customizable press release news feed in the world

Sun Pharma Completes Taro Merger

Taro Shareholders Approve Merger with Sun Pharma

Taro Provides Results for Year Ended March 31, 2024

$TARO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd.

SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)

SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)

$TARO SEC Filings

SEC Form 15F-12B filed by Taro Pharmaceutical Industries Ltd.

SEC Form 25-NSE filed by Taro Pharmaceutical Industries Ltd.

Amendment: SEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd.

$TARO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Taro Pharm downgraded by H.C. Wainwright with a new price target

HC Wainwright & Co. reiterated coverage on Taro Pharmaceutical Indus with a new price target

HC Wainwright & Co. reiterated coverage on Taro Pharmaceutical Indus with a new price target

$TARO Leadership Updates

Live Leadership Updates

Taro Appoints New Chief Financial Officer

Taro Announces Resignation of Chief Financial Officer

$TARO Market Insights

Live Market Insights

Sun Pharmaceutical And Taro Pharmaceutical Industries' Merger Agreement Was Approved By The Affirmative Vote Of Taro Shareholders

Taro Pharmaceutical Indus Q4 Adj EPS $0.43 Beats $0.31 Estimate, Sales $164.941M Beat $156.062M Estimate

Krensavage Asset Management Remains Opposed to Sun Pharma's Predatory Bid for Taro Pharma

$TARO Financials

Live finance-specific insights

Taro to Release Third Quarter Results on January 25, 2024

Taro to Release Second Quarter Results on October 26, 2023

Taro to Release First Quarter Results on July 26, 2023

Recent Analyst Ratings for
$TARO

$TARO
Press Releases

$TARO
Large Ownership Changes

$TARO
SEC Filings

$TARO
Analyst Ratings

$TARO
Leadership Updates

$TARO
Market Insights

$TARO
Financials